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Introduction
The prescribed use of second-generation antipsychotics (SGAs) for children and adolescents with mental
disorders has increased by 114% from 2005 to 2009 in Canada, even though the number of children in
Canada has decreased slightly over the same period of time1. The increased use of SGAs has caused more
metabolic complications such as: weight gain, hyperlipidemia, insulin resistance, and type 2 diabetes2. In
order to combat metabolic complications, the Canadian Alliance for Monitoring Effectiveness and Safety
of Antipsychotics in Children (CAMESA) guideline group has proposed evidence-based recommendations2.
The objective of the study was to evaluate for the first time the rate of metabolic screening for children and
adolescents under SGAs in Calgary. There has been no previous reported data available in Calgary regarding
the screening.
Methods
A chart review was done for 57 active patients in Neuropsychiatry Services (NPS) of Alberta Health Services,
Calgary, Canada.
NPS is a multi-disciplinary outpatient clinic that specializes in mental health and neurological disorders of
children and adolescents. All the patients were under 19 years old. The data for drug use, height, weight,
BP, BMI, waist circumference, HDL, LDL, fasting triglyceride, fasting total cholesterol, and fasting plasma
glucose was recorded in the study (Tables 1.0 & 1.1). The data was only included if it was taken in NPS or
if it was requested from any other services by a health care provider in NPS at least once.
Results
Out of the 57 patients in NPS, 22 patients were prescribed SGAs. The most common diagnosis in SGA-treated
patients were attention deficit hyperactivity disorder (ADHD) (11.3%), extrapyramidal disorders (6.4%),
and intellectual disabilities (6.4%). Patients treated with SGAs were more likely to go through metabolic
monitoring than patients treated without SGAs. However, the rate of metabolic monitoring for both of the
study groups was disappointing. Moreover, the real life clinical scenario might be gloomier than it seem. A
patient might need to go through metabolic monitoring more than once depending on the frequency and
length of use of SGA. For each specific screening category, a patient was considered to be monitored even if
they were only monitored once.
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Discussion and Conclusion
The low rate of metabolic screening for patients with SGAs suggest that even evidence-based national clinical
practice recommendations such as CAMESA treatment recommendations cannot produce any tangible
benefits unless they are implemented in the clinical setting. In an ideal world, all the patients should have
their height, weight, and BP measured regularly by their physicians. The lack of physical examinations and
lab results for patients treated with antipsychotics in NPS was indeed disappointing, yet there is hope. After
the implementation of Metabolic Monitoring Training Program (MMTP) in Vancouver Coastal Health Child
& Youth Mental Health Team, height measurement increased from 39% to 89%, fasting glucose measurement
increased from 34% to 89%, lipid profile measurement increased from 32% to 89%, and SGA usage decreased
by 56%3. The results from MMTP implementation has shown NPS and others that monitoring rate can be
improved through proper implementation. Therefore, pediatric psychiatric patients in NPS with SGAs ought
to go through more frequent and regular metabolic monitoring to reduce adverse side effects.
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